Strategies Preventing Contrast-Induced Nephropathy After Coronary Angiography: A Comprehensive Meta-Analysis and Systematic Review of 125 Randomized Controlled Trials
Restricted accessReview articleFirst published online May, 2017
Strategies Preventing Contrast-Induced Nephropathy After Coronary Angiography: A Comprehensive Meta-Analysis and Systematic Review of 125 Randomized Controlled Trials
This systematic review with meta-analysis sought to determine the strength of evidence for the effects of hydration (sodium bicarbonate [SB] and normal saline [NS]), supplementations (N-acetylcysteine [NAC] and vitamin C), and some common drugs (adenosine antagonists [AAs], statins, loop diuretics, and angiotensin-converting enzyme inhibitors [ACEIs]) on the incidence of contrast-induced nephropathy (CIN) and requirement for hemodialysis after coronary angiography. After screening, a total of 125 trials that reported outcomes were identified. Pooled analysis indicated beneficial effects of SB versus NS (odds ratio [OR] = 0.73; 95% confidence interval [CI]: 0.56-0.94; P = .01), NAC (OR = 0.79; 95% CI: 0.70-0.88; P = .001), vitamin C (OR = 0.64; 95% CI: 0.45-0.89; P = .01), statins (OR = 0.45; 95% CI: 0.35-0.57; P = .001), AA (OR = 0.28; 95% CI: 0.14-0.47; P = .001), loop diuretics (OR = 0.97; 95% CI: 0.33-2.85; P = .9), and ACEI (OR = 1.06; 95% CI: 0.69-1.61; P = .8). Overall, hydration with SB, use of supplements, such as NAC and vitamin C, and administration of statins and AA should always be considered for the prevention of CIN after coronary angiography.
PavlidisANJonesDASirkerAMathurASmithEJ. Prevention of contrast-induced acute kidney injury after percutaneous coronary intervention for chronic total coronary occlusions. Am J Cardiol. 2015;115(6):844–851. doi:10.1016/j.amjcard.2014.12.047.
2.
NarulaAMehranRWeiszG. Contrast-induced acute kidney injury after primary percutaneous coronary intervention: results from the HORIZONS-AMI substudy. Eur Heart J. 2014;35(23):1533–1540. doi:10.1093/eurheartj/ehu063.
3.
HoshiTSatoAKakefudaY. Preventive effect of statin pretreatment on contrast-induced acute kidney injury in patients undergoing coronary angioplasty: propensity score analysis from a multicenter registry. Int J Cardiol. 2014;171(2):243–249. doi:10.1016/j.ijcard.2013.12.017.
4.
AzzaliniLSpagnoliVLyHQ. Contrast-induced nephropathy: From pathophysiology to preventive strategies. Can J Cardiol. 2016;32(2):247–255.
5.
AndreucciMFagaTPisaniASabbatiniMRussoDMichaelA. Prevention of contrast-induced nephropathy through a knowledge of its pathogenesis and risk factors. Sci World J. 2014;2014:823169. doi:10.1155/2014/823169.
6.
SolomonRDerayG. How to prevent contrast-induced nephropathy and manage risk patients: practical recommendations. Kidney Int. 2006;69(100):S51–S53.
7.
JadadARMooreRACarrollD. Assessing the quality of reports of randomized clinical trials: is blinding necessary?Control Clin Trials. 1996;17(1):1–12.
8.
BoucekPHavrdovaTOliyarnykO. Prevention of contrast-induced nephropathy in diabetic patients with impaired renal function: a randomized, double blind trial of sodium bicarbonate versus sodium chloride-based hydration. Diabetes Res Clin Pract2013;101:303–8
9.
BrarSSShenAYJorgensenMB. Sodium bicarbonate vs sodium chloride for the prevention of contrast medium-induced nephropathy in patients undergoing coronary angiography: a randomized trial. JAMA. 2008;300(9):1038–1046.
10.
AlessandriNLanziLGaranteCM. Prevention of acute renal failure post-contrast imaging in cardiology: a randomized study. Eur Rev Med Pharmacol Sci. 2013;17(suppl 1):13–21.
11.
AdolphEHoldt-LehmannBChatterjeeT. Renal Insufficiency Following Radiocontrast Exposure Trial (REINFORCE): a randomized comparison of sodium bicarbonate versus sodium chloride hydration for the prevention of contrast-induced nephropathy. Coron Artery Dis. 2008;19(6):413–419.
12.
YangKLiuWRenWLvS. Different interventions in preventing contrast-induced nephropathy after percutaneous coronary intervention. Int Urol Nephrol. 2014;46(9):1801–1807.
13.
Vasheghani-FarahaniASadighGKassaianSE. Sodium bicarbonate in preventing contrast nephropathy in patients at risk for volume overload: a randomized controlled trial. J Nephrol. 2010;23(2):216–223.
14.
Vasheghani-FarahaniASadighGKassaianSE. Sodium bicarbonate plus isotonic saline versus saline for prevention of contrast-induced nephropathy in patients undergoing coronary angiography: a randomized controlled trial. Am J Kidney Dis. 2009;54(4):610–618.
15.
ThayssenPLassenJFJensenSE. Prevention of contrast-induced nephropathy with N-acetylcysteine or sodium bicarbonate in patients with ST-segment-myocardial infarction: a prospective, randomized, open-labeled trial. Circ Cardiovasc Interv. 2014;7(2):216–224.
16.
UedaHYamadaTMasudaM. Prevention of contrast-induced nephropathy by bolus injection of sodium bicarbonate in patients with chronic kidney disease undergoing emergent coronary procedures. Am J Cardiol. 2011;107(8):1163–1167.
17.
TamuraAGotoYMiyamotoK. Efficacy of single-bolus administration of sodium bicarbonate to prevent contrast-induced nephropathy in patients with mild renal insufficiency undergoing an elective coronary procedure. Am J Cardiol. 2009;104(7):921–925.
18.
ShavitLKorenfeldRLifschitzMButnaruASlotkiI. Sodium bicarbonate versus sodium chloride and oral N-acetylcysteine for the prevention of contrast-induced nephropathy in advanced chronic kidney disease. J Interv Cardiol. 2009;22(6):556–563.
19.
Recio-MayoralAChaparroMPradoB. The reno-protective effect of hydration with sodium bicarbonate plus N-acetylcysteine in patients undergoing emergency percutaneous coronary intervention: the RENO Study. J Am Coll Cardiol. 2007;49(12):1283–1288.
20.
RatcliffeJAThiagarajahPChenJ. Prevention of contrast-induced nephropathy: a randomized controlled trial of sodium bicarbonate and N-acetylcysteine. Int J Angiol. 2009;18(4):193–197.
21.
PakfetratMNikooMHMalekmakanL. A comparison of sodium bicarbonate infusion versus normal saline infusion and its combination with oral acetazolamide for prevention of contrast-induced nephropathy: a randomized, double-blind trial. Int Urol Nephrol. 2009;41(3):629–634.
22.
OzcanEEGuneriSAkdenizB. Sodium bicarbonate, N-acetylcysteine, and saline for prevention of radiocontrast-induced nephropathy. A comparison of 3 regimens for protecting contrast-induced nephropathy in patients undergoing coronary procedures. A single-center prospective controlled trial. Am Heart J. 2007;154(3):539–544.
23.
MotohiroMKamihataHTsujimotoS. A new protocol using sodium bicarbonate for the prevention of contrast-induced nephropathy in patients undergoing coronary angiography. Am J Cardiol. 2011;107(11):1604–1608.
24.
MertenGJBurgessWPGrayLV. Prevention of contrast-induced nephropathy with sodium bicarbonate: a randomized controlled trial. JAMA. 2004;291(19):2328–2334.
25.
MasudaMYamadaTMineT. Comparison of usefulness of sodium bicarbonate versus sodium chloride to prevent contrast-induced nephropathy in patients undergoing an emergent coronary procedure. Am J Cardiol. 2007;100(5):781–786.
26.
MaioliMTosoALeonciniM. Sodium bicarbonate versus saline for the prevention of contrast-induced nephropathy in patients with renal dysfunction undergoing coronary angiography or intervention. J Am Coll Cardiol. 2008;52(8):599–604.
27.
LeeSWKimWJKimYH. Preventive strategies of renal insufficiency in patients with diabetes undergoing intervention or arteriography (the PREVENT trial). Am J Cardiol. 2011;107(10):1447–1452.
28.
KocFOzdemirKAltunkasF. Sodium bicarbonate versus isotonic saline for the prevention of contrast-induced nephropathy in patients with diabetes mellitus undergoing coronary angiography and/or intervention: a multicenter prospective randomized study. J Investig Med. 2013;61(5):872–877.
29.
KlimaTChristAMaranaI. Sodium chloride vs. sodium bicarbonate for the prevention of contrast medium-induced nephropathy: a randomized controlled trial. Eur Heart J. 2012;33(16):2071–2079.
30.
HeguilénRMListeAAPayaslianMOrtembergMGAlbarracínLMBernasconiAR. N-acethyl-cysteine reduces the occurrence of contrast-induced acute kidney injury in patients with renal dysfunction: a single-center randomized controlled trial. Clin Exp Nephrol. 2013;17(3):396–404.
31.
HafizAMJanMFMoriN. Prevention of contrast-induced acute kidney injury in patients with stable chronic renal disease undergoing elective percutaneous coronary and peripheral interventions: randomized comparison of two preventive strategies. Catheter Cardiovasc Interv. 2012;79(6):929–937.
32.
GomesVOLasevitchRLimaVC. Hydration with sodium bicarbonate does not prevent contrast nephropathy: a multicenter clinical trial. Arq Bras Cardiol. 2012;99(6):1129–1134.
33.
CastiniDLucreziottiSBosottiL. Prevention of contrast-induced nephropathy: a single center randomized study. Clin Cardiol. 2010;33(3):E63–E68.
34.
BriguoriCAiroldiFD’AndreaD. Renal Insufficiency Following Contrast Media Administration Trial (REMEDIAL): a randomized comparison of 3 preventive strategies. Circulation. 2007;115(10):1211–1217.
35.
MahmoodiKSohrabiBIlkhchooyiFMalakiMKhanianiMEHemmatiM. The efficacy of hydration with normal saline versus hydration with sodium bicarbonate in the prevention of contrast-induced nephropathy. Heart Views. 2014;15(2):33–36.
36.
Inda-FilhoAJCaixetaAMangginiMSchorN. Do intravenous N-acetylcysteine and sodium bicarbonate prevent high osmolal contrast-induced acute kidney injury? A randomized controlled trial. PLoS One. 2014;9(9):e107602. doi:10.1371/journal.pone.0107602.
37.
ManariAMagnavacchiPPuggioniE. Acute kidney injury after primary angioplasty: effect of different hydration treatments. J Cardiovasc Med (Hagerstown). 2014;15(1):60–67.
38.
BeyazalHCaliskanZUtaçC. Comparison of effects of isotonic sodium chloride with diltiazem in prevention of contrast-induced nephropathy. Ren Fail. 2014;36(3):351–355.
39.
YeganehkhahMRIraniradLDorriF. Comparison between three supportive treatments for prevention of contrast-induced nephropathy in high-risk patients undergoing coronary angiography. Saudi J Kidney Dis Transpl. 2014;25(6):1217–1223.
40.
SolomonRGordonPManoukianSV. Randomized trial of bicarbonate or saline study for the prevention of contrast-induced nephropathy in patients with CKD. Clin J Am Soc Nephrol. 2015;10(9):1519–1524.
41.
ACT Investigators. Acetylcysteine for prevention of renal outcomes in patients undergoing coronary and peripheral vascular angiography: main results from the randomized Acetylcysteine for Contrast-induced nephropathy Trial (ACT). Circulation. 2011;124(11):1250–1259.
42.
AlbabtainMAAlmasoodAAlshurafahHAlamriHTamimH. Efficacy of ascorbic acid, N-acetylcysteine, or combination of both on top of saline hydration versus saline hydration alone on prevention of contrast-induced nephropathy: a prospective randomized study. J Interv Cardiol. 2013;26(1):90–96.
43.
AminiMSalarifarMAmirbaiglooAMasoudkabirFEsfahaniF. N-acetylcysteine does not prevent contrast-induced nephropathy after cardiac catheterization in patients with diabetes mellitus and chronic kidney disease: a randomized clinical trial. Trials. 2009;10:45.
44.
BakerCSWraggAKumarSDe PalmaRBakerLRKnightCJ. A rapid protocol for the prevention of contrast-induced renal dysfunction: the RAPPID study. J Am Coll Cardiol. 2003;41(12):2114–2118.
45.
BaskurtMOkcunBAbaciO. N-acetylcysteine versus N-acetylcysteine + theophylline for the prevention of contrast nephropathy. Eur J Clin Invest. 2009;39(9):793–799.
46.
BerwangerOCavalcantiABSousaAM. Acetylcysteine for the prevention of renal outcomes in patients with diabetes mellitus undergoing coronary and peripheral vascular angiography: a substudy of the acetylcysteine for contrast-induced nephropathy trial. Circ Cardiovasc Interv. 2013;6(2):139–145.
47.
BriguoriCManganelliFScarpatoP. Acetylcysteine and contrast agent-associated nephrotoxicity. J Am Coll Cardiol. 2002;40(2):298–303.
48.
AzmusADGottschallCManicaA. Effectiveness of acetylcysteine in prevention of contrast nephropathy. J Invasive Cardiol. 2005;17(2):80–84.
49.
CalabròPBianchiRCrisciM. Use and efficacy of saline hydration and N-acetyl cysteine to prevent contrast-induced nephropathy in low-risk populations undergoing coronary artery angiography. Intern Emerg Med. 2011;6(6):503–507.
50.
CarbonellNBlascoMSanjuánR. Intravenous N-acetylcysteine for preventing contrast-induced nephropathy: a randomised trial. Int J Cardiol. 2007;115(1):57–62.
51.
CarbonellNSanjuánRBlascoMJordáAMiguelA. N-acetylcysteine: short-term clinical benefits after coronary angiography in high-risk renal patients. Rev Esp Cardiol. 2010;63(1):12–19.
52.
CoyleLCRodriguezAJeschkeRESimon-LeeAAbbottKCTaylorAJ. Acetylcysteine In Diabetes (AID): a randomized study of acetylcysteine for the prevention of contrast nephropathy in diabetics. Am Heart J. 2006;151(5):1032.e9-e12.
53.
Diaz-SandovalLJKosowskyBDLosordoDW. Acetylcysteine to prevent angiography-related renal tissue injury (the APART trial). Am J Cardiol. 2002;89(3):356–358.
54.
DurhamJDCaputoCDokkoJ. A randomized controlled trial of N-acetylcysteine to prevent contrast nephropathy in cardiac angiography. Kidney Int. 2002;62(6):2202–2207.
FungJWSzetoCCChanWW. Effect of N-acetylcysteine for prevention of contrast nephropathy in patients with moderate to severe renal insufficiency: a randomized trial. Am J Kidney Dis. 2004;43(5):801–808.
57.
GoldenbergIShechterMMatetzkyS. Oral acetylcysteine as an adjunct to saline hydration for the prevention of contrast-induced nephropathy following coronary angiography. A randomized controlled trial and review of the current literature. Eur Heart J. 2004;25(3):212–218.
58.
GomesVOPoli de FigueredoCECaramoriP. N-acetylcysteine does not prevent contrast induced nephropathy after cardiac catheterisation with an ionic low osmolality contrast medium: a multicenter clinical trial. Heart. 2005;91(6):774–778.
59.
GulelOKelesTEraslanHAydogduSDikerEUlusoyV. Prophylactic acetylcysteine usage for prevention of contrast nephropathy after coronary angiography. J Cardiovasc Pharmacol. 2005;46(4):464–467.
60.
GünebakmazOKayaMGKocF. Does nebivolol prevent contrast-induced nephropathy in humans?Clin Cardiol. 2012;35(4):250–254.
61.
HengAECellarierEAublet-CuvelierB. Is treatment with N-acetylcysteine to prevent contrast-induced nephropathy when using bicarbonate hydration out of date?Clin Nephrol. 2008;70(6):475–484.
62.
HölscherBHeitmeyerCFobkerMBreithardtGSchaeferRMReineckeH. Predictors for contrast media-induced nephropathy and long-term survival: prospectively assessed data from the randomized controlled Dialysis-Versus-Diuresis (DVD) trial. Can J Cardiol. 2008;24(11):845–850.
63.
JafferyZVermaAWhiteCJ. A randomized trial of intravenous N-acetylcysteine to prevent contrast induced nephropathy in acute coronary syndromes. Catheter Cardiovasc Interv. 2012;79(6):921–926.
64.
KayJChowWHChanTM. Acetylcysteine for prevention of acute deterioration of renal function following elective coronary angiography and intervention: a randomized controlled trial. JAMA. 2003;289(5):553–558.
65.
KimBJSungKCKimBS. Effect of N-acetylcysteine on cystatin C-based renal function after elective coronary angiography (ENABLE Study): a prospective, randomized trial. Int J Cardiol. 2010;138(3):239–245.
66.
KinbaraTHayanoTOhtaniNFurutaniYMoritaniKMatsuzakiM. Efficacy of N-acetylcysteine and aminophylline in preventing contrast-inducednephropathy. J Cardiol. 2010;55(2):174–179.
67.
KocFOzdemirKKayaMG. Intravenous N-acetylcysteine plus high-dose hydration versus high-dose hydration and standard hydration for the prevention of contrast-induced nephropathy: CASIS— a multicenter prospective controlled trial. Int J Cardiol. 2012;155(3):418–423.
68.
MacNeillBDHardingSABazariH. Prophylaxis of contrast-induced nephropathy in patients undergoing coronary angiography. Catheter Cardiovasc Interv. 2003;60(4):458–461.
69.
MinerSEDzavikVNguyen-HoP. N-acetylcysteine reduces contrast-associated nephropathy but not clinical events during long-term follow-up. Am Heart J. 2004;148(4):690–695.
70.
OchoaAPellizzonGAddalaS. Abbreviated dosing of N-acetylcysteine prevents contrast-induced nephropathy after elective and urgent coronary angiography and intervention. J Interv Cardiol. 2004;17(3):159–165.
71.
OldemeyerJBBiddleWPWurdemanRLMoossANCichowskiEHillemanDE. Acetylcysteine in the prevention of contrast-induced nephropathy after coronary angiography. Am Heart J. 2003;146(6):E23.
72.
SeyonRAJensenLAFergusonIAWilliamsRG. Efficacy of N-acetylcysteine and hydration versus placebo and hydration in decreasing contrast-induced renal dysfunction in patients undergoing coronary angiography with or without concomitant percutaneous coronary intervention. Heart Lung. 2007;36(3):195–204.
73.
ShyuKGChengJJKuanP. Acetylcysteine protects against acute renal damage in patients with abnormal renal function undergoing a coronary procedure. J Am Coll Cardiol. 2002;40(8):1383–1388.
74.
WangJHSubeqYMTsaiWCLeeRPHsuBG. Intravenous N-acetylcysteine with saline hydration improves renal function and ameliorates plasma total homocysteine in patients undergoing cardiac angiography. Ren Fail. 2008;30(5):527–533.
75.
ThieleHHildebrandLSchirdewahnC. Impact of high-dose N-acetylcysteine versus placebo on contrast-induced nephropathy and myocardial reperfusion injury in unselected patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. The LIPSIA-N-ACC (Prospective, Single-Blind, Placebo-Controlled, Randomized Leipzig Immediate PercutaneouS Coronary Intervention Acute Myocardial Infarction N-ACC) Trial. J Am Coll Cardiol2010;55:2201–2209.
76.
BrueckMCengizHHoeltgenR. Usefulness of N-acetylcysteine or ascorbic acid versus placebo to prevent contrast-induced acute kidney injury in patients undergoing elective cardiac catheterization: a single-center, prospective, randomized, double-blind, placebo-controlled trial. J Invasive Cardiol2013;25:276–83.
77.
WebbJGPateGEHumphriesKH. A randomized controlled trial of intravenous N-acetylcysteine for the prevention of contrast-induced nephropathy after cardiac catheterization: lack of effect. Am Heart J. 2004;148(3):422–429.
78.
KeferJMHanetCEBoitteSWilmotteLDe KockM. Acetylcysteine, coronary procedure and prevention of contrast-induced worsening of renal function: which benefit for which patient?Acta Cardiol. 2003;58(6):555–560.
79.
ArabmomeniMNajafianJAbdar EsfahaniMSamadiMMirbagherL. Comparison between theophylline, N-acetylcysteine, and theophylline plus N-acetylcysteine for the prevention of contrast-induced nephropathy. ARYA Atheroscler. 2015;11(1):43–49.
80.
KumarABhawaniGKumariNMurthyKSLalwaniVRajuChN. Comparative study of renal protective effects of allopurinol and N-acetyl-cysteine on contrast induced nephropathy in patients undergoing cardiac catheterization. J Clin Diagn Res. 2014;8(12):HC03–HC07.
81.
ChongEPohKKLuQ. Comparison of combination therapy of high-dose oral N-acetylcysteine and intravenous sodium bicarbonate hydration with individual therapies in the reduction of Contrast-induced Nephropathy during Cardiac Catheterisation and Percutaneous Coronary Intervention (CONTRAST): a multi-centre, randomised, controlled trial. Int J Cardiol. 2015;201:237–242.
82.
BoscheriAWeinbrennerCBotzekBReynenKKuhlischEStrasserRH. Failure of ascorbic acid to prevent contrast-media induced nephropathy in patients with renal dysfunction. Clin Nephrol. 2007;68(5):279–286.
83.
DvoršakBKaničVEkartRBevcSHojsR. Ascorbic acid for the prevention of contrast-induced nephropathy after coronary angiography in patients with chronic renal impairment: a randomized controlled trial. Ther Apher Dial. 2013;17(4):384–390.
84.
ZhouLChenH. Prevention of contrast-induced nephropathy with ascorbic acid. Intern Med2012;51:531–535.
85.
SpargiasKAlexopoulosEKyrzopoulosS. Ascorbic acid prevents contrast-mediated nephropathy in patients with renal dysfunction undergoing coronary angiography or intervention. Circulation2004;110:2837–2842.
86.
TosoAMaioliMLeonciniM. Usefulness of atorvastatin (80 mg) in prevention of contrast-induced nephropathy in patients with chronic renal disease. Am J Cardiol2010;105:288–292.
87.
AcikelSMuderrisogluHYildirirA. Prevention of contrast-induced impairment of renal function by short-term or long-term statin therapy in patients undergoing elective coronary angiography. Blood Coagul Fibrinolysis. 2010;21(8):750–757.
88.
HanYZhuGHanL. Short-term rosuvastatin therapy for prevention of contrast-induced acute kidney injury in patients with diabetes and chronic kidney disease. J Am Coll Cardiol. 2014;63(1):62–70.
89.
JoSHKooBKParkJS. Prevention of radiocontrast medium-induced nephropathy using short-term high-dose simvastatin in patients with renal insufficiency undergoing coronary angiography (PROMISS) trial—a randomized controlled study. Am Heart J. 2008;155(3):499.e1-e8.
90.
LeonciniMTosoAMaioliMTropeanoFVillaniSBellandiF. Early high-dose rosuvastatin for contrast-induced nephropathy prevention in acute coronary syndrome: Results from the PRATO-ACS Study (Protective Effect of Rosuvastatin and Antiplatelet Therapy On contrast-induced acute kidney injury and myocardial damage in patients with Acute Coronary Syndrome). J Am Coll Cardiol. 2014;63(1):71–79.
91.
LiWFuXWangY. Beneficial effects of high-dose atorvastatin pretreatment on renal function in patients with acute ST-segment elevation myocardial infarction undergoing emergency percutaneous coronary intervention. Cardiology. 2012;122(3):195–202.
92.
OzhanHErdenIOrduS. Efficacy of short-term high-dose atorvastatin for prevention of contrast-induced nephropathy in patients undergoing coronary angiography. Angiology. 2010;61(7):711–714.
93.
PattiGRicottiniENuscaA. Short-term, high-dose atorvastatin pretreatment to prevent contrast-induced nephropathy in patients with acute coronary syndromes undergoing percutaneous coronary intervention (from the ARMYDA-CIN [atorvastatin for reduction of myocardial damage during angioplasty – contrast-induced nephropathy] trial. Am J Cardiol. 2011;108(1):1–7.
94.
QuintavalleCFioreDDe MiccoF. Impact of a high loading dose of atorvastatin on contrast-induced acute kidney injury. Circulation. 2012;126(25):3008–3016.
95.
BidramPRoghaniFSaneiH. Atorvastatin and prevention of contrast induced nephropathy following coronary angiography. J Res Med Sci. 2015;20(1):1–6.
96.
AbaciOArat OzkanAKocasC. Impact of rosuvastatin on contrast-induced acute kidney injury in patients at high risk for nephropathy undergoing elective angiography. Am J Cardiol. 2015;115(7):867–871.
97.
ShehataMHamzaM. Impact of high loading dose of atorvastatin in diabetic patients with renal dysfunction undergoing elective percutaneous coronary intervention: a randomized controlled trial. Cardiovasc Ther. 2015;33(2):35–41.
98.
BilasyMEOrabyMAIsmailHMMakladyFA. Effectiveness of theophylline in preventing contrast-induced nephropathy after coronary angiographic procedures. J Interv Cardiol. 2012;25(4):404–410.
99.
RohaniA. Effectiveness of aminophylline prophylaxis of renal impairment after coronary angiography in patients with chronic renal insufficiency. Indian J Nephrol. 2010;20(2):80–83.
100.
AbizaidASClarkCEMintzGS. Effects of dopamine and aminophylline on contrast-induced acute renal failure after coronary angioplasty in patients with preexisting renal insufficiency. Am J Cardiol. 1999;83(2):260–263, A5.
101.
HuberWSchipekCIlgmannK. Effectiveness of theophylline prophylaxis of renal impairment after coronary angiography in patients with chronic renal insufficiency. Am J Cardiol. 2003;91(10):1157–1162.
102.
KapoorAKumarSGulatiSGambhirSSethiRSSinhaN. The role of theophylline in contrast-induced nephropathy: a case–control study. Nephrol Dial Transplant. 2002;17(11):1936–1941.
103.
MatejkaJVarvarovskyIVojtisekP. Prevention of contrast-induced acute kidney injury by theophylline in elderly patients with chronic kidney disease. Heart Vessels. 2010;25(6):536–542.
104.
MalhisMAl-BitarSAl-Deen ZaiatK. The role of theophylline in prevention of radiocontrast media-induced nephropathy. Saudi J Kidney Dis Transpl. 2010;21(2):276–283.
105.
GuGQLuRCuiW. Low-dose furosemide administered with adequate hydration reduces contrast-induced nephropathy in patients undergoing coronary angiography. Cardiology. 2013;125(2):69–73.
106.
MajumdarSRKjellstrandCMTymchakWJHervas-MaloMTaylorDATeoKK. Forced euvolemic diuresis with mannitol and furosemide for prevention of contrast-induced nephropathy in patients with CKD undergoing coronary angiography: a randomized controlled trial. Am J Kidney Dis. 2009;54(4):602–609.
107.
MarenziGFerrariCMaranaI. Prevention of contrast nephropathy by furosemide with matched hydration: the MYTHOS (Induced Diuresis With Matched Hydration Compared to Standard Hydration for Contrast Induced Nephropathy Prevention) trial. JACC Cardiovasc Interv. 2012;5(1):90–97.
108.
ShemiraniHPourrmoghaddasM. A randomized trial of saline hydration to prevent contrast-induced nephropathy in patients on regular captopril or furosemide therapy undergoing percutaneous coronary intervention. Saudi J Kidney Dis Transpl. 2012;23(2):280–285.
109.
SolomonRWernerCMannDD’EliaJSilvaP. Effects of saline, mannitol, and furosemide to prevent acute decreases in renal function induced by radiocontrast agents. N Engl J Med. 1994;331(21):1416–1420.
110.
OguzhanNCilanHSipahiogluM. The lack of benefit of a combination of an angiotensin receptor blocker and calcium channel blocker on contrast-induced nephropathy in patients with chronic kidney disease. Ren Fail. 2013;35(4):434–439.
111.
GuptaRKKapoorATewariSSinhaNSharmaRK. Captopril for prevention of contrast-induced nephropathy in diabetic patients: a randomised study. Indian Heart J. 1999;51(5):521–526.
112.
ToprakOCiritMBayataSYeşilMAslanSL. [The effect of pre-procedural captopril on contrast-induced nephropathy in patients who underwent coronary angiography]. Anadolu Kardiyol Derg. 2003;3(2):98–103.
113.
HashemiMKharaziAShahidiS. Captopril for prevention of contrast induced nephropathy in patients undergoing coronary angioplasty: a double blind placebo controlled clinical trial. J Res Med Sci. 2005;10(6):305–308.
114.
LiXMCongHLLiTTHeLJZhouYJ. Impact of benazepril on contrast-induced acute kidney injury for patients with mild to moderate renal insufficiency undergoing percutaneous coronary intervention. Chin Med J (Engl). 2011;124(14):2101–2106.
115.
RosenstockJLBrunoRKimJK. The effect of withdrawal of ACE inhibitors or angiotensin receptor blockers prior to coronary angiography on the incidence of contrast-induced nephropathy. Int Urol Nephrol2008;40:749–755.
116.
WolakTAlievERogachevB. Renal safety and angiotensin II blockade medications in patients undergoing non-emergent coronary angiography: a randomized controlled study. Isr Med Assoc J2013;15:682–687.
117.
BaineyKRRahimSEtheringtonK. Effects of withdrawing vs continuing renin-angiotensin blockers on incidence of acute kidney injury in patients with renal insufficiency undergoing cardiac catheterization: results from the Angiotensin Converting Enzyme Inhibitor/Angiotensin Receptor Blocker and Contrast Induced Nephropathy in Patients Receiving Cardiac Catheterization (CAPTAIN) trial. Am Heart J. 2015;170(1):110–116.
118.
JangJSJinHYSeoJS. Sodium bicarbonate therapy for the prevention of contrast-induced acute kidney injury – a systematic review and meta-analysis. Circ J. 2012;76(9):2255–2265.
119.
Ali-Hassan-SayeghSMirhosseiniSJRahimizadehE. Current status of sodium bicarbonate in coronary angiography: an updated comprehensive meta-analysis and systematic review. Cardiol Res Pract. 2015;2015:690308.
120.
Ali-Hassan-SayeghSMirhosseiniSJGhodratipourZ. Protective effects of anti-oxidant supplementations on contrast induced nephropathy after coronary angiography: an updated and comprehensive meta-analysis and systematic review. Kardiol Pol. 2016118. doi:10.5603/KP.a2016.0007.
121.
PapapetrouAMorisDPatelisN. Oxidative stress and total antioxidant status during internal carotid artery clamping with or without shunting: an experimental pilot study. Med Sci Monit Basic Res. 2015;21:200–205.
122.
LiaoJKLaufsU. Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol2005;45:89–118.
123.
ChadeARZhuXYGrandeJPKrierJDLermanALermanLO. Simvastatin abates development of renal fibrosis in experimental renovascular disease. J Hypertens. 2008;26(8):1651–1660.
124.
LeeJMParkJJeonKH. Efficacy of short-term high-dose statin pretreatment in prevention of contrast-induced acute kidney injury: updated study-level meta-analysis of 13 randomized controlled trials. PLOS ONE. 2014;9(11):e111397.
125.
SinghNLeeJZHuangJJ. Benefit of statin pretreatment in prevention of contrast-induced nephropathy in different adult patient population: systematic review and meta-analysis. Open Heart. 2014;1(1):e000127.
126.
ErleyCMHeyneNBurgertKLangankeJRislerTOsswaldH. Prevention of radiocontrast-induced nephropathy by adenosine antagonists in rats with chronic nitric oxide deficiency. J Am Soc Nephrol. 1997;8(7):1125–1132.
127.
ArendLJBakrisGLBurnettJCJrMegerianCSpielmanWS. Role for intrarenal adenosine in the renal hemodynamic response to contrast media. J Lab Clin Med. 1987;110(4):406–411.
128.
ArakawaKSuzukiHNaitohM. Role of adenosine in the renal responses to contrast medium. Kidney Int. 1996;49(5):1199–1206.
129.
DaiBLiuYFuLLiYZhangJMeiC. Effect of theophylline on prevention of contrast-induced acute kidney injury: a meta-analysis of randomized controlled trials. Am J Kidney Dis. 2012;60(3):360–370.
130.
WuZZhangHJinW. The effect of renin-angiotensin-aldosterone system blockade medications on contrast-induced nephropathy in patients undergoing coronary angiography: a meta-analysis. PLOS ONE. 2015;10(6):e0129747.
131.
DuanNZhaoJLiZ. Furosemide with saline hydration for prevention of contrast-induced nephropathy in patients undergoing coronary angiography: a meta-analysis of randomized controlled trials. Med Sci Monit. 2015;21:292–297.
132.
ReyesAJ. The increase in serum uric acid concentration caused by diuretics might be beneficial in heart failure. Eur J Heart Fail. 2005;7(4):461–467.
133.
RobinsonPCStampLK. The management of gout: much has changed. Aust Fam Physician. 2016;45(5):299–302.
134.
HigginsJPAltmanDGGøtzschePC. The Cochrane Collaboration’s tool for assessing risk of bias in randomized trials. BMJ. 2011;343:d5928.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
